![]() |
||||
|
|
||||
|
|
||||
CONTRACEPTION: Extended- and continuous-cycle oral contraceptivesFrom: Hope Waltman (anonymous@obgyn.net)Sat, 9 Aug 2008 20:24:23 -0500 (CDT)
Pharmacotherapy. 2008 Aug;28(8):1033-40.Related Articles, Links Extended- and continuous-cycle oral contraceptives. Shrader SP, Dickerson LM. Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina. Abstract Five new oral contraceptives, classified as extended- or continuous-cycle oral contraceptives, have been approved by the United States Food and Drug Administration. These agents have various combinations of estrogen and progestin, and different effects on the length of women's menstrual cycles. Usually they shorten the duration of menses, decrease the frequency of menses to 4 times/year, or completely eliminate menses. These new oral contraceptives are given in the following regimens: 24 days followed by placebo for 4 days (24/4), 84 days followed by placebo for 7 days (84/7), or continuously (without placebo). These agents contain ethinyl estradiol 20 mug-drospirenone 3 mg (24/4); ethinyl estradiol 20 mug-norethindrone 1 mg (24/4); ethinyl estradiol 30 mug-levonorgestrel 150 mug (84/7); ethinyl estradiol 30 mug-levonorgestrel 150 mug (84/7) with very low-dose ethinyl estradiol (10 mug/day) for 7 days; and ethinyl estradiol 20 mug-levonorgestrel 90 mug continuously. Clinical trials have demonstrated that extended- and continuous-cycle oral contraceptives are as effective in preventing pregnancy as traditional oral contraceptives. These new agents also have similar adverse effects; however, the only significantly different adverse effect compared with traditional oral contraceptives in clinical trials was change in bleeding pattern. These oral contraceptives are associated with more breakthrough bleeding and spotting than the traditional pills. Long-term effects on efficacy and safety are not known, as these new products generally have been used for only 1-2 years. Extended- and continuous-cycle oral contraceptives are a new option for women desiring decreased menses or for whom decreased menses may alleviate symptoms of coexisting medical conditions. http://www.ncbi.nlm.nih.gov/pubmed/18657019?dopt=Abstract Regards, Hope Waltman, Fibroid Forum and WH Forum Moderator http://www.hopeforfibroids.org http://www.doctorsinfoweb.com/doctors.htm UTERINE FIBROIDS INFO: http://www.obgyn.net/fibroid-resource-center/ http://www.obgyn.net/fibroid-resource-center/?page=articles/patient_articles
|
|
Return to ![]()
Report TECHNICAL Problems ONLY to: webmaster@obgyn.net
Last Updated: Wed Dec 2 06:55:53 2009
Women's Insurance Checklist from Auto Insurance Quote
home | medical professionals | women | industry | forums | international